The Incredible True Story of Henrietta Lacks the Most Important Woman in Modern Medicine – PEOPLE.com

Henrietta Lacks was just 30 years old when she discovered a lump on her cervix while in her bathtub at home.

A private-care doctor referred her to Johns Hopkins Hospital for further testing and she was diagnosed with cancer in January 1951. Lacks, the wife of a steelworker and a mother of five, was treated with radiation and sent home, but she was hospitalized the following August. She died at the age of 31 two months later.

But thats not where her story ends.

Without her knowledge or permission, doctors harvested samples of Lacks cervical tissue during her treatments and discovered her cancerous cells were not like any other theyd seen they were able to duplicate in labs and stay alive. This meant that the same sample of tissue could be tested multiple times for research, making her cell line immortal.

Research using Lacks cells helped spur numerous medical breakthroughs, include vaccines, cancer treatments and in vitro fertilization. But, for decades, her family was kept in the dark about her second life and were never compensated for her contributions.

Now, Oprah Winfrey is executive-producing and starring in anHBO movie adaptation of The Immortal Life of Henrietta Lacks the New York Times best seller by Rebecca Skloot that detailed how Lacks cells came to be known as the HeLa line, and how its existence has impacted the family she left behind.

They did what theyd never had another human cell do duplicate itself and then duplicate itself and then duplicate itself, Winfrey, who plays Lacks daughter Deborah in the movie, tells PEOPLE during the latest edition of The Jess Cagle Interview, excerpted in this weeks issue. (You can watch a video clip of it above.) Thats why its called the Immortal Life of Henrietta Lacks, because her cells even now as we speak are still replicating somewhere in some tube.

HeLa cells have contributed to medical advancements like the polio vaccine and have been used in gene mapping and AIDS and cancer research. And although Lacks died in 1951, her family didnt know that her cells were still alive in labs all over the country. That all changed in 1973, when doctors requested blood samples from them after HeLa inadvertently contaminated other samples.

Her family didnt know that anyone had taken her cells until much later on. Once they discovered it, trying to figure out how it all happened and how it unraveled and multi-millions of dollars, now billions of dollars, have been made off of the cells is the story of the Immortal Life of Henrietta Lacks, Winfrey says during the interview, which took place at The London West Hollywood in Beverly Hills.

The movie, airingApril 22, explores the familys hardships after finding out about the existence of the cells and their thwarted attempts to gather more information.

And though Skloot played by Rose Byrne in the movie originally set out to tell Lacks tale, the authorquickly realized the story went far beyond the woman behind the HeLa cells when she talked to Lacks daughter Deborah for the first time in 1999.

To me, it was not only about the woman, but what that doesto a family, Skloot tells PEOPLE. Deborah and I were both driven by this same obsessive passion to just answer these questions: Who was she? What happened? What can be done to make it so it doesnt happen again?

Although Deborah and Skloot shared this common goal, it took years for the second-youngest Lacks child to trust her. The family had gone through years of alleged mistreatment from medical professionals and were burned by people who had tried taking advantage of their connection to the famous HeLa cells. Skloot had to overcome these insecurities and show Deborah she could be trusted with her mothers story.

For me, the process of winning her trust was about figuring out why she was afraid, she says. I knew something happened to her that made her scared of me. It was definitely like the way you see it in the movie where we would go forward and good things would happen and she would panic and push me away. Usually it was because something happened related to her traumatic experiences and she would get scared and really challenge me.

Theircontentious relationship continued as Deborahs older brothers repeatedly tried to stop her from talking to Skloot, and tensions boiled over one day in a hotel room when Deborah, frightened and defensive, pushed Skloot against a wall. Still, the twocontinued to work together, eventually establishing a trust and friendship that led them to discover more about the mother Deborah never got to know.

Deborah died in 2009 before the book was published, but she did get to see her mother for the first time thanks to her work with the author.In 2001, Skloot, Deborah and her brother Zakariyya got the chance to visit Johns Hopkins and see the HeLa cells.

It was one of the most incredible and powerful moments of my life, Skloot says. That was the closest thing theyd ever seen to their mother being alive since they have no memory of her. It was beautiful for them to be in the presence of her in a way that felt the closest to her being alive. She knew that that wasnt her mother obviously, but it was like being able to have closure in a really beautiful way.

Link:
The Incredible True Story of Henrietta Lacks the Most Important Woman in Modern Medicine - PEOPLE.com

Two new Series A rounds inject $72M into regenerative medicine and NASH – MedCity News


MedCity News
Two new Series A rounds inject $72M into regenerative medicine and NASH
MedCity News
Frequency is built around its so-called Progenitor Cell Activation (PCA) platform developed by Robert Langer and Jeffrey Karp from MIT and Harvard Medical School. Progenitor cells are slightly more specialized than stem cells. And while they typically ...
Frequency Therapeutics Announces $32 Million Series A Financing to Support Clinical Development of a First-in-Class ...Business Wire (press release)

all 9 news articles »

Excerpt from:
Two new Series A rounds inject $72M into regenerative medicine and NASH - MedCity News

James Rothman appointed Sterling Professor of Cell Biology – Yale News

James E. Rothman, newly appointed as a Sterling Professor of Cell Biology, is one of the world's most distinguished biochemists and cell biologists. For his work on how molecular messages are transmitted inside and outside of human cells, he was awarded a Nobel Prize in 2013.

A Sterling Professorship is one of the universitys highest faculty honors.

Rothman helped reveal the mechanism that allows cellular compartments called vesicles to transmit information both in the interior of the cell and to the surrounding environment. The fusion of vesicles and cellular membranes, a process called exocytosis, is basic to life and occurs in organisms as diverse as yeast and humans. Exocytosis underlies physiological functions ranging from the secretion of insulin to the regulation of the brain neurotransmitters responsible for movement, perception, memory, and mood.

Rothmans current research concerns the biophysics of membrane fusion and its regulation in exocytosis; the dynamics of the Golgi apparatus at super-resolution; and the use of bio-inspired design in nanotechnology.

After graduating from Yale College with a degree in physics, Rothman earned a Ph.D. in biological chemistry from Harvard Medical School. He conducted postdoctoral research at the Massachusetts Institute of Technology before moving to the Stanford School of Medicine as an assistant professor. He continued his research at Princeton University, where he became the founding chair of the Department of Cellular Biochemistry and Biophysics at Memorial Sloan-Kettering Cancer Center and vice chair of the Sloan-Kettering Institute. Prior to coming to Yale in 2008, Rothman served on the faculty of Columbia Universitys College of Physicians and Surgeons, where he was a professor in the Department of Physiology and Biophysics, the Clyde and Helen Wu Professor of Chemical Biology, and director of the Columbia Genome Center.

Rothman serves as chair of the Yale School of Medicines Department of Cell Biology and as director of the Nanobiology Institute on Yales West Campus.

He has received numerous awards and honors in recognition of his work on vesicle trafficking and membrane fusion, including the King Faisal International Prize for Science, the Gairdner Foundation International Award, the Lounsbery Award of the National Academy of Sciences, the Heineken Foundation Prize of the Netherlands Academy of Sciences, the Louisa Gross Horwitz Prize of Columbia University, the Lasker Basic Science Award, the Kavli Prize in Neuroscience, the Massry Prize, and the E.B. Wilson Medal. He is a member of the National Academy of Sciences and its Institute of Medicine, and is a fellow of the American Academy of Arts and Sciences.

View post:
James Rothman appointed Sterling Professor of Cell Biology - Yale News

Brain cell therapy offers hope for Parkinson’s patients – CBS News

Scientists from Sweden say they have made significant progress in the search for a new treatment for Parkinsons disease.

Though the research, published in Nature Biotechnology, is still preliminary and the therapy not yet ready to be tested in humans, experts say it could one day help the millions of people living with the neurodegenerative disease.

Researchers from the Karolinska Institute tested whether certain brain cells could be manipulated to take on the role of those destroyed by Parkinsons.

Play Video

The longest fight of Muhammad Ali's life was with Parkinson's disease. Even when the heavyweight champion was at his peak, signs of the disorder ...

They first showed in laboratory experiments that it was possible to convert non-neural human brain cells called astrocytes into dopamine neurons, which degenerate and die in the brains of people suffering from Parkinsons disease.

These are two specialized cells that do not spontaneously convert into one another, study author Ernest Arenas, a professor at Karolinska Institutes Department of medical biochemistry and biophysics, told CBS News. However, when we used diverse chemicals and genes important for the development of immature brain cells into functional dopamine neurons, we found that it was possible to convert astrocytes into dopamine neurons.

The researchers then tested whether this could be done in mice with Parkinsons and if the therapy would improve their condition.

After two weeks, they reported that astrocytes in the brains of the mice started to become dopamine neurons. At five weeks, the mice recovered some of their motor functions such as posture, motility and walking pattern.

Current treatments for Parkinsons only address symptoms, not the cause of the disease itself.

While much more research is needed before the treatment can be tested in humans, Arenas says it could one day lead to an approach to change the course of disease and halt or even reverse motor deficits in Parkinsons disease patients.

Aside from being in early stages, the research is limited in several ways, the study authors say.

First, Arenas notes that although dopamine neurons are the main cell type affected in Parkinsons disease -- and those responsible for the characteristic motor symptoms -- other cell types are affected, particularly as the disease progresses. Therefore, additional strategies to treat these other cell types will be needed in the future.

Additionally, this type of therapy would involve surgery, and therefore could be riskier compared to other treatments on the market. However, with people living longer in most societies, more severe forms of disease are currently being seen, Arenas said, and people are suffering longer.

We thus think that cell replacement therapies, because of its potential to change the course of disease, may become the method of choice in the future, he said.

The authors say now that they know the treatment technique is possible, future research will concentrate on making it safer and developing it into a method that could be applied in a clinical setting.

Our goal and hope is that all these studies will lead to the development of a safe and efficient cell replacement therapy for Parkinsons disease in which no cell transplantation or immunosuppression is necessary, Arenas said.

2017 CBS Interactive Inc. All Rights Reserved.

Here is the original post:
Brain cell therapy offers hope for Parkinson's patients - CBS News

Taking Cell Therapy one Step Further with this Boost Reagent – Labiotech.eu (blog)

Cell therapy is revolutionizing medicine, heres how the latest technology can help overcome the major challenges stopping it from taking over the market.

Offering unprecedented possibilities to treat some of the most challenging diseases, cell therapy is stealing the show in the biotech space. Strimvelis, the first hematopoietic stem cell (HSC) gene therapy is already treating rare genetic diseases. In less than a year, CAR-T therapy is expected to hit the market and revolutionize the treatment of cancer. And in the not-so-far future, cell therapy could even eradicate HIV or put an end to diabetes, which is reaching epidemic proportions in Western countries.

The first cell therapies have already been on the market for a few years, and analysts are confident that the numbers will quickly grow over the years. The stem cell therapy market alone is expected to hit 57Bn ($61Bn) by 2022, and the upcoming CAR-T technology will reach an impressive 8Bn ($8.5Bn) in the next decade.

Although the potential is definitely there, researchers are still looking for ways of making these therapies cheaper, safer and more effective. Currently, not all patients are suited to receive cell therapy due to scientific or economic challenges. The advent of allogeneic therapies is addressing the financial obstacles, but what about efficiency?

One of the key elements to building a successful cell therapy are viral vectors, which are used to deliver the necessary DNA sequences to engineer the cells. Lentiviral vectors are a common choice because they have a rather larger capacity and enable long-lasting genetic expression.

They are specially researched for ex-vivo treatment of hematopoietic stem cells and primary T-cells. The percentage of cells that can be reached, however, often remains low, and the number of gene copy numbers per cell can be extremely variable.

Finding a solution to this challenge is unfortunately not as simple as increasing the virus load. Cells that carry a surplus of copies integrated into their DNA are more prone to mutations that affect their survival and put the safety of the patient in danger. This is an essential factor taken into account during the regulatory phase to determine whether a therapy can make it to the market or not.

How can we then improve the efficacy of transduction without affecting the health of the cells and the safety of the therapy? In the lab, researchers often use enhancers such as polybrene, a polymer that can increase the efficacy of transduction of viral DNA. However, this substance is not applicable in a clinical context because of its heightened cell toxicity.

To overcome these challenges, scientists at SIRION Biotech got down to work and screened for compounds that could improve the fusion of the viral and cell membranes. The result was a technology with the potential to solve a major problem in the development of cell therapies, with DNA delivery reaching an impressive 80% of hematopoietic stem cells while keeping the copy numbers down to the ideal value of 3 to 5 per cell.

This technology, called LentiBOOST, works its magic simply by adding a non-toxic polymer to the mixture during transduction. It has already been accepted as an element of clinical trials from phase I to phase III and its possibilities seem unlimited. One of SIRIONs partners, the Heinrich Pette Institute in Hamburg, is studying the potential of LentiBOOST to improve transduction in a therapy intended to actively remove HIV from infected blood cells and induce long-lasting resistance against the virus.

With applications ranging from cancer to infectious disease, cell therapy is definitely going to change medicine. Technology like LentiBOOST is helping these amazing developments materialize with a boost to both their efficacy and safety.

You can find more information on LentiBOOST at SIRION Biotechs website!

Images from Montri Thipsorn, vchal /Shutterstock; SIRION Biotech

Link:
Taking Cell Therapy one Step Further with this Boost Reagent - Labiotech.eu (blog)

DCGI approves Regenerative Medical’s stem cell therapy for cartilage defects – Livemint

Mumbai: Regenerative Medical Services Pvt. Ltd on Wednesday said that the Drug Controller General of India (DCGI) recently approved its stem cell-based therapy to treat cartilage defects.

Chondron, its cartilage repair procedure, uses the bodys own cartilage cells that are cultured, multiplied and implanted into the patients damaged joint leading to new cartilage regeneration and avoiding the need for early joint replacement. This is the first stem cell-therapy product to be approved in India.

We are creating new age cartilage regeneration procedure which optimizes the chances of healing due to the use of the bodys own cells. We will tie up with hospitals to promote it; we have received interest from around 200 hospitals, chief executive officer and managing director Yash Sanghavi said.

The company has capacity to culture 1,000-1,200 patient samples annually, which it plans to enhance to 10,000-12,000 samples in next three years, chief scientific officer Satyen Sanghavi, said.

The Mumbai-based company, started in 2009, has invested around Rs70-75 crore on development of Chondron and conducted clinical trials on 350 patients. It is looking to raise funds for capacity expansion and marketing of the cell therapy.

We are looking to raise Rs40-50 crore through equity dilution and have already appointed bankers, Sanghavi said. The treatment, he said, is likely to cost around Rs2 lakh, which is almost the same or slightly lower than the price of a knee replacement surgery.

First Published: Wed, Apr 12 2017. 09 11 PM IST

Read the original:
DCGI approves Regenerative Medical's stem cell therapy for cartilage defects - Livemint

Fundraising appeal for stem cell treatment after chickenpox triggers … – News Shopper

A desperate father has launched a fundraising bid to treat his sonafter he was diagnosed with a debilitating central nervous system disease.

Tiago Gouveia was diagnosed with Spinal Cerebellar Ataxia Type Seven (SCA7) after chickenpox triggered the genetic condition, inherited from father Marvino.

The four-year-old can no longer walk unaided and his weight has dropped to just 1.7 stones - 11kg - since last May - half of what he should normally weigh for his age.

He has also developed kidney disease as a result of his illness and could go blind, lose his ability to speak and no longer be able to swallow if not treated.

Dad Marvino, 40, who lives in Malvern Road, Orpington, is now hoping to raise 30,000 to fund stem cell treatment in Bangkok, Thailand, which could cure Tiago.

He said: "He was born well, and he was a normal child growing up until the age of two-and-a-half.

"In May 2015, he was with his cousin who had chickenpox, and it triggered the disease.

"It's a genetic condition, and I carry the gene - my mum, sister and niece all have it.

"After six to seven months, Tiago stopped walking and got a lot more wobbly before it came to a point where he couldn't walk anymore.

"He's lost lots of weight and for now his sight is okay, but it will get worse.

"He was vomiting every day until he got a gastrostomy on April 4, and we're hoping that will stop it - he had been fed through a tube since November but it was making him sick.

"He developed nephrosis, which affects his kidneys, so now he's on steroids as well as seven or eight other types of medication.

"It came to the point where we said we can't wait to fix him, so we decided to start the fundraising page for stem cell treatment."

Tiago has inherited the condition from finance worker Marvino, whose mother, sister and niece also have the genetic disorder.

His Geneva-based sister Canisia Brunier, 52, her daughter Melissa, 21, and Marvino's mother Latifa Goveia, 71, who lives in his native Portugal, all suffer from SCA7.

Marvino added: "He's got a bad gene, and because he's young and male the disease is developing much more quickly.

"He weighs 11kg and he should be double that, he's very skinny and you can see all his bones.

"Sometimes he's in a good mood but the medication gives him really bad moods.

"I don't have words to describe it, it's just too much."

Marvino and full-time carer wife Rosa Gouveia, 38, are also parents to Andre, 11, who does not have SCA7.

The family are now hoping to raise enough money for Tiago to undertake crucial stem cell treatment.

They have already raised 7,200 on JustGiving but need more.

Marvino said: "We're hoping we can get this money to help him, it's been very tough seeing him suffer like this - he's always sick.

"The stem cell treatment could help a lot or maybe even cure him and the doctor says he has a very good chance of improving.

"He's getting worse every day so need to do it soon.

"We've had a lot of support from our friends and family and we're really happy with how much we've raised, but we're still trying to spread the word."

The fundraising page is here

See the article here:
Fundraising appeal for stem cell treatment after chickenpox triggers ... - News Shopper

Human Embryonic Stem Cells Market Size Worth $1.06 Billion by … – Yahoo Finance

SAN FRANCISCO, April 11, 2017 /PRNewswire/ --

The global human embryonic stem cells (hESCs) marketis anticipated to reach USD 1.06 billion by 2025, according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.

(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.

In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.

Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.

However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.

Browse full research report with TOC on "Human Embryonic Stem Cells (hESC) Market Analysis By Application (Regenerative Medicines, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Country (U.S., UK, Germany, Japan, China), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/human-embryonic-stem-cell-market

Further key findings from the report suggest:

Browse related reports by Grand View Research:

Grand View Research has segmented the human embryonic stem cells market on the basis of application and region:

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. Thecompany provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

The rest is here:
Human Embryonic Stem Cells Market Size Worth $1.06 Billion by ... - Yahoo Finance

Brain cell therapy ‘promising’ for Parkinson’s disease – BBC News


BBC News
Brain cell therapy 'promising' for Parkinson's disease
BBC News
Scientists believe they have found a way to treat and perhaps reverse Parkinson's disease, by making replacement cells to mend the damaged brain. They say human brain cells can be coaxed to take over the job of the ones that are destroyed in Parkinson's.
Cell Therapy 2.0: Reprogramming the Brain's Own Cells for Parkinson's TreatmentScientific American
Brain Cell Therapy Reverses Parkinson's-Like Symptoms In MiceHuffington Post UK
Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapyThe San Diego Union-Tribune
STAT -NHS Choices
all 66 news articles »

Follow this link:
Brain cell therapy 'promising' for Parkinson's disease - BBC News

GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote – Genetic Engineering & Biotechnology News

GE Healthcare said today it has acquired Asymptote for an undisclosed price in a deal that the buyer said would strengthen its cell therapy portfolio with technologies designed to enable the cryopreservation of cellular materials.

Asymptote specializes in cryochain technology for sensitive cellular therapies, with the goal of significantly lowering the risk of contamination found in conventional processes.

The companys integrated suite of cryochain hardware, software, and consumables is designed to support cGMP and maintain the potency of cellular therapies by enabling ultra-low-temperature freezing during production, followed by thawing prior to administering to patients in clinical settings.

Asymptotes VIA FreezeTM range delivers liquid nitrogen-free cryopreservation, while the soon-to-be released VIA ThawTM series thaws deeply frozen cells using a dry conduction (water-free) process. The companys web-based my.Cryochain software platform is designed to support cell therapy companies as they scale their cryopreservation and thawing processes by synchronizing with the VIA Freeze and VIA Thaw products to standardize freezing and thawing programs across multiple sites, improving the visibility of remote processes.

Asymptotes high-quality offering takes us another step forward in our vision to industrialize cell therapy, and in providing reliable and high-quality services for our customers and patients around the world, Ger Brophy, Ph.D., general manager of GE Healthcares cell therapy business, said in a statement.

Added Asymptote founder and CEO John Morris, Ph.D.: The acquisition gives us the opportunity to reach a larger audience through the local specialist GE Cell Therapy team, provides us with a strong platform for our product launches, and allows us to significantly scale up our product development.

GE Healthcare reasons that demand for manufacturing and clinical delivery will increase as the cell therapy market grows and develops. The company cited statistics from the Alliance for Regenerative Medicine showing 804 clinical trials underway by the end of last year for cell therapies, as well as gene-modified cell therapies, gene therapies, and tissue-engineering therapies.

The acquisition of Asymptote is GE Healthcares latest move toward growing its cell therapy offerings. In July 2016, GE acquired Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed sum. Three months earlier, GE Ventures teamed up with Mayo Clinic Ventures to launch Vitruvian Networks,a collaboration providing cloud-based software systems and manufacturing services for cell and gene therapies.

And in January 2016, GE Healthcare and the Government of Canada each committed C$20 million ($15 million) to launch the [emailprotected] Cell Therapy Centre of Excellence, created to promote new technologies for the production of cellular therapies in Toronto.

Link:
GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote - Genetic Engineering & Biotechnology News